Literature DB >> 28236204

[Consolidative local therapy in oligometastatic NSCLC without progression after first-line chemotherapy].

Daniel Buergy1, Frederik Wenz2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28236204     DOI： 10.1007/s00066-017-1113-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

Review 1.  Surgical treatment of oligometastatic non-small cell lung cancer.

Authors:  Joachim Pfannschmidt; Hendrik Dienemann
Journal:  Lung Cancer       Date:  2010-09       Impact factor: 5.705

2.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).

Authors:  Atif J Khan; Par S Mehta; Thomas W Zusag; Philip D Bonomi; L Penfield Faber; Susan Shott; Ross A Abrams
Journal:  Radiother Oncol       Date:  2006-10-16       Impact factor: 6.280

3.  Oligometastases.

Authors:  S Hellman; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

4.  Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".

Authors:  Juliane Rieber; Jan Streblow; Lorenz Uhlmann; Michael Flentje; Marciana Duma; Iris Ernst; Oliver Blanck; Andrea Wittig; Judit Boda-Heggemann; Robert Krempien; Fabian Lohaus; Nathalie Desirée Klass; Michael J Eble; Detlef Imhoff; Henning Kahl; Cordula Petersen; Sabine Gerum; Christoph Henkenberens; Sonja Adebahr; Peter Hass; Elsge Schrade; Thomas G Wendt; Guido Hildebrandt; Nicolaus Andratschke; Florian Sterzing; Matthias Guckenberger
Journal:  Lung Cancer       Date:  2016-04-26       Impact factor: 5.705

5.  Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.

Authors:  Tetsuya Inoue; Norio Katoh; Hidefumi Aoyama; Rikiya Onimaru; Hiroshi Taguchi; Shunsuke Onodera; Satoshi Yamaguchi; Hiroki Shirato
Journal:  Jpn J Clin Oncol       Date:  2010-04-20       Impact factor: 3.019

6.  Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.

Authors:  Kyle E Rusthoven; Susan F Hammerman; Brian D Kavanagh; Michael J Birtwhistle; Mark Stares; D Ross Camidge
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

7.  Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.

Authors:  Tommy Sheu; John V Heymach; Stephen G Swisher; Ganesh Rao; Jeffrey S Weinberg; Reza Mehran; Mary Frances McAleer; Zhongxing Liao; Thomas A Aloia; Daniel R Gomez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-09       Impact factor: 7.038

Review 8.  Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

Authors:  Chee-Seng Tan; David Gilligan; Simon Pacey
Journal:  Lancet Oncol       Date:  2015-09       Impact factor: 41.316

9.  Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.

Authors:  Judit Boda-Heggemann; Dietmar Dinter; Christel Weiss; Anian Frauenfeld; Kerstin Siebenlist; Ulrike Attenberger; Martine Ottstadt; Frank Schneider; Ralf-Dieter Hofheinz; Frederik Wenz; Frank Lohr
Journal:  Radiat Oncol       Date:  2012-06-18       Impact factor: 3.481

10.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316
  10 in total
  1 in total

1.  Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients.

Authors:  Xiao-Wei Cheng; Wen-Hua Leng; Chun-Ling Mu
Journal:  World J Clin Cases       Date:  2020-11-06       Impact factor: 1.337
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.